Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Azevedo

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Clinics (Sao Paulo, Brazil)|July 30, 2015
Cytomegalovirus infection in transplant recipientsLuiz Sergio Azevedo, Lígia Camera Pierrotti, Edson Abdala, et al.
Journal of Hepatology|August 1, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaGeorge Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
NEJM Evidence|February 6, 2024
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Revista Do Instituto De Medicina Tropical De Sao Paulo|January 22, 2025
Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individualsKarina Takesaki Miyaji, Karim Yaqub Ibrahim, Vanessa Infante, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinics (Sao Paulo, Brazil)|July 30, 2015
Cytomegalovirus infection in transplant recipientsLuiz Sergio Azevedo, Lígia Camera Pierrotti, Edson Abdala, et al.
Journal of Hepatology|August 1, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaGeorge Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
NEJM Evidence|February 6, 2024
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Revista Do Instituto De Medicina Tropical De Sao Paulo|January 22, 2025
Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individualsKarina Takesaki Miyaji, Karim Yaqub Ibrahim, Vanessa Infante, et al.
Pageof 2